Universal Predischarge Screening for Neonatal Hyperbilirubinemia

Report from Evidence Review
Secretary's Advisory Committee on Heritable Disorders in Newborns and Children
January 27, 2011

James M. Perrin, MD
Professor of Pediatrics, Harvard Medical School
Director, Center for Child and Adolescent Health Policy
MassGeneral Hospital for Children
Recent Progress and Activities

Critical Congenital Cyanotic Heart Disease
- Final review presented September 2010
- Paper in development

Neonatal Hyperbilirubinemia
- Preliminary (literature only) evidence review presented today

Publications

Review of the Evidence Process (Calonge, Green, Kemper, Evidence team)
Workgroup Team Members

Key authors:
- John P. Co, MD, MPH, MGH/Harvard
- Alixandra A. Knapp, MS, MGH/Harvard
- Danielle Metterville, MS, CGC, MGH/Harvard
- Lisa A. Prosser, PhD, University of Michigan Health System

Program director:
- James M. Perrin, MD, MGH/Harvard

Staff:
- Marsha Browning, MD, MPH
- Anne Marie Comeau, PhD, New England Newborn Screening Program/UMass Medical School
- Nancy S. Green, MD, Columbia University
- Alex R. Kemper, MD, MPH, MS, Duke University
- Denise Queally, JD, Consumer, PKU Family Coalition
Materials Included in Preliminary Review

• Detailed literature review methods

• Summary of evidence from literature review

• Tables highlighting key data from abstracted articles

• Bibliography
Neonatal Hyperbilirubinemia
Overview

• Elevated total bilirubin level in a newborn

• Multiple etiologies

• Detectable risk factor for acute bilirubin encephalopathy (ABE) and kernicterus

• Primary concern reflects potential for neurotoxic effects of severe hyperbilirubinemia
Conceptual Framework

- **General population of newborns**
  - Screening for Neonatal Hyperbilirubinemia
  - Risk assessment of Hyperbilirubinemia

- **Treatment of Hyperbilirubinemia**

- **Diagnosis of:**
  - Normal bilirubin level
  - Acute bilirubin encephalopathy
  - Kernicterus

- **Harms of testing and/or identification**

- **Harms of treatment/other interventions**
  - Reduced rate of acute bilirubin encephalopathy and kernicterus;
  - Improvement in morbidity, and/or other outcomes
Rationale for Review

1. Hyperbilirubinemia can lead to kernicterus, with permanent damage to the central nervous system (CNS) and death

2. Early identification of risk factors for kernicterus, including elevated serum bilirubin, may allow interventions to lower risk

3. TcB or TSB measurement widely available

4. Treatment is widely available to prevent severe neonatal hyperbilirubinemia (phototherapy, exchange transfusion (EcT))
Case Definition

- Technical Expert Panel helped to refine case definition

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vinod Bhutani, MD, PhD</td>
<td>Lucile Salter Packard Children’s Hospital, Stanford University School of Medicine, Palo Alto, California</td>
</tr>
<tr>
<td>Lois Johnson-Hamerman, MD</td>
<td>Pennsylvania Center for Kernicterus, Philadelphia, Pennsylvania</td>
</tr>
<tr>
<td>M. Jeffrey Maisels, MD</td>
<td>Beaumont Hospital, Michigan</td>
</tr>
<tr>
<td>Ann Stark, MD</td>
<td>Texas Children's Hospital, Baylor College of Medicine, Houston, Texas</td>
</tr>
<tr>
<td>David Stevenson, MD</td>
<td>Lucile Packard Children's Hospital at Stanford, Stanford University School of Medicine, Palo Alto, California</td>
</tr>
</tbody>
</table>
Case Definition

**Neonatal Hyperbilirubinemia**
- Clinically significant hyperbilirubinemia in the neonatal period as indicated by TSB levels >95th percentile for age in hours, which may require follow-up and treatment.

**Acute Bilirubin Encephalopathy (ABE)**
- Variable acute manifestations of bilirubin toxicity present in the first weeks of life. Symptoms include neurological manifestations, somnolence, hypotonia, loss of the Moro reflex, followed by an irreversible stage characterized by hypertonia of the extensor muscle groups. Fever and/or a high-pitched cry may be present.

**Chronic Bilirubin Encephalopathy (Kernicterus)**
- Chronic and permanent brain damage caused by bilirubin toxicity and characterized by four clinical manifestations 1) movement disorder (athetosis, dystonia, spasticity, hypotonia), 2) auditory dysfunction, 3) oculomotor impairment and, 4) dental enamel hypoplasia.

Hyperbilirubinemia has been associated with other longer term neurologic dysfunction, and we will also address these associations in this review.
Methods for Evidence Review

- Preliminary report (today)
  - Systematic literature review to summarize evidence from published studies on the natural history, screening, treatment and economics of screening for neonatal hyperbilirubinemia

- Final report
  - Updated literature review
  - Consultation with multiple neonatal hyperbilirubinemia investigators and consumers, as well as assessment of unpublished data
Methods for Literature Search

• Searched MEDLINE for all relevant screening studies published over a 20 year period

• Completed searches combining the National Library of Medicine Medical Subject Heading (MeSH) “hyperbilirubinemia”, “bilirubin encephalopathy”, and “kernicterus”

• Reviewed references from nomination form and bibliography of review papers

• Three investigators (JPC, AAK, DRM) reviewed all abstracts and independently abstracted a subset of the articles (20% overlap)
Systematic Literature Review

Findings

• January 1990 – September 2010
  • Medline, OVID In-Process and Other Non-Indexed Citations
  • English language only
  • Human studies only
  • In cases of duplicate publications, selected the most recent or complete versions

• 2,742 abstracts selected for preliminary review
• 172 articles selected for in-depth review
• 99 articles met all inclusion criteria for abstraction
### Papers Meeting Review Criteria

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Number of papers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experimental intervention</td>
<td>4</td>
</tr>
<tr>
<td>Cohort study</td>
<td>17</td>
</tr>
<tr>
<td>Case-control study</td>
<td>8</td>
</tr>
<tr>
<td>Case series</td>
<td>57</td>
</tr>
<tr>
<td>Sample size ≤ 10</td>
<td>6</td>
</tr>
<tr>
<td>Sample size 11 to 50</td>
<td>5</td>
</tr>
<tr>
<td>Sample size 51 to 100</td>
<td>4</td>
</tr>
<tr>
<td>Sample size 101 to 1000</td>
<td>19</td>
</tr>
<tr>
<td>Sample size ≥ 1001</td>
<td>23</td>
</tr>
<tr>
<td>Economic Evaluation</td>
<td>2</td>
</tr>
<tr>
<td>Cross-sectional study</td>
<td>11</td>
</tr>
<tr>
<td>Total studies</td>
<td>99</td>
</tr>
</tbody>
</table>
Key Questions - Condition

• Is severe neonatal hyperbilirubinemia well-defined? When does it appear clinically? What are the known risk factors, if any?

• What evidence is available regarding the relationship between severe neonatal hyperbilirubinemia and kernicterus?

• How well characterized is kernicterus? When does it appear clinically?
Hyperbilirubinemia Incidence

- Neonatal jaundice: 10-15%
- Bilirubin > 25 mg/dl: 0.14%
- Bilirubin > 29 mg/dl: 0.01%
- Kernicterus: 0.001-0.002% (1-2/100,000)
Changes in Incidence

- 1991-2000, California databases
  - Readmission rate for jaundice increased through 1998
  - Factors associated with increased likelihood of readmission included GA 34-39 weeks, birth weight <2500 g, male, Medicaid or private insurance and Asian race

- 1988-2005, USA databases
  - Rates of newborn jaundice diagnoses fell from 1988–1993 and increased from 1997-2005
  - Number of newborns with a diagnosis of kernicterus declined throughout this period, from ~5.1/100,000 in 1988 to ~1.5/100,000 from 1994-2005

- 1979-2002, Pilot USA Kernicterus Registry
  - Increase in voluntarily reported cases rose from 2 between 1979-1984 and peaking at 21 between 1993-1994 and again between 2001-2002
Risk Factors

Hyperbilirubinemia
• Prematurity
• Asian race
• Isoimmunization
• Hemolytic disease
• Low birth weight

Kernicterus
• Prematurity
• Asian race
• Early discharge
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Spectrum of Severity

• Studies describe spectrum of acute and chronic manifestations of neonatal hyperbilirubinemia

• Differences in study design limit the ability to compare data

• Summarized in Table 5 of evidence review
Acute Manifestations

• Acute manifestations
  – Abnormal VEP, BAEP and MRI findings
  – Symptoms of central nervous system involvement
  – Abnormal behavioral assessments

• Some studies show association between the severity of these symptoms and TSB level

• Some studies indicate symptoms are transient and resolve
Chronic Manifestations

• Neurodevelopmental issues
  – 7 studies show significantly increased risk of abnormal neurodevelopment (delayed gross motor, fine motor, and adaptive and social skills)
  – 6 studies suggest resolved or minor effects of hyperbilirubinemia on neurodevelopmental outcomes

• Auditory issues
  – 3 studies indicate a direct relationship between elevated TSB levels (>20 mg/dL) and risk of developing long-term hearing disorders
Kernicterus

- Kernicterus
  - 125 cases of kernicterus followed by the Pilot USA Kernicterus Registry - 6/125 infants died in the first year of life
  - Studies suggest characteristic changes on MRI
  - No evidence in the literature of a specific bilirubin level confirmed to lead to kernicterus
  - Kernicterus has been reported in apparently healthy term newborns without hemolysis
Kernicterus

- Pilot USA Kernicterus Registry data (n=125)
  - Contributing factors: G6PD deficiency (26/125), hemolysis (25/125), birth trauma (18/125)
  - Co-morbidities: sepsis, dehydration, infection

- Retrospective chart review, 1999-2000 (n=12)
  - G6PD deficiency (7/12), dehydration (3/12), sepsis (1/12)
Condition - Remaining Questions

• What evidence is available regarding the relationship between severe neonatal hyperbilirubinemia and kernicterus?

• When does kernicterus appear clinically?
Key Questions - Screening

- What methods exist to screen newborns for neonatal hyperbilirubinemia?

- How do timing of screening after birth, gestational age, threshold levels, and other considerations affect the number of infants identified with or being at significant risk for developing neonatal hyperbilirubinemia?

- What is the predictive validity of using the risk assessment nomogram to predict risk of developing hyperbilirubinemia?
Key Questions - Screening

• What are the recommended follow-up and monitoring procedures for newborns found to have an intermediate risk level by bilirubin screening?

• Do outpatient facilities have the capacity to handle follow-up visits for screen positive infants?

• Has there been population-based pilot screening?

• What are the potential harms or risks associated with screening?
Screening Methods

Bilirubin estimations/measurements

- Visual Assessment
- Transcutaneous bilirubin (TcB)
- Total serum bilirubin (TSB)

Risk prediction

- Hour specific nomogram
## Screening - TSB

### TSB screening for subsequent significant hyperbilirubinemia

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Cutoff, Timing</th>
<th>Subsequent Hyperbilirubinemia</th>
<th>Sens. (%)</th>
<th>Spec. (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agarwal et al., 2002</td>
<td>220 infants ≥35 weeks gestation</td>
<td>&gt;6mg/dL, 24 hours</td>
<td>≥17mg/dl &gt;24 hours of age</td>
<td>95</td>
<td>70.6</td>
<td>27.2</td>
<td>99.3</td>
</tr>
<tr>
<td>Alpay et al., 2000</td>
<td>498 healthy term newborns ≥38 weeks gestation</td>
<td>≥6mg/dL, 24 hours</td>
<td>≥17mg/dl &gt;24 hours of age</td>
<td>90</td>
<td>65.3</td>
<td>26.2</td>
<td>97.9</td>
</tr>
<tr>
<td>Carbonell et al., 2001</td>
<td>2004 healthy term newborns of 37-42 weeks gestational age</td>
<td>≥6mg/dL, 24 hours</td>
<td>≥17mg/dl &gt;72 hours of age</td>
<td>100</td>
<td>60</td>
<td>13</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥9mg/dL, 48 hours</td>
<td></td>
<td>98</td>
<td>45</td>
<td>10</td>
<td>99.6</td>
</tr>
<tr>
<td>Prasarnphanich &amp; Somlaw, 2007</td>
<td>1983 healthy term neonates</td>
<td>12mg/dL, 48-72 hours</td>
<td>≥13mg/dL 49-72 hours of age, ≥15mg/dl &gt;72 hours of age</td>
<td>36.6</td>
<td>87.9</td>
<td>15.3</td>
<td>95.9</td>
</tr>
<tr>
<td>Seidman et al., 1999</td>
<td>1177 healthy term newborns</td>
<td>&gt;5mg/dL, 8-24 hours</td>
<td>&gt;10 mg/dL on day 2, &gt;14 mg/dL on day 3, &gt;17 mg/dL on days 4 and 5 of life</td>
<td>63.1</td>
<td>94.2</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
## Screening - TcB

### TcB screening for elevated TSB values

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Cutoff, Timing, Placement</th>
<th>TSB comparison value</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boo &amp; Ishak, 2007</td>
<td>345 healthy term neonates with hyperbilirubinemia</td>
<td>14.6 mg/dL, median 70 hours, forehead</td>
<td>&gt;17.5 mg/dL</td>
<td>100</td>
<td>39.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11.7 mg/dL, median 70 hours, sternum</td>
<td>&gt;17.5 mg/dL</td>
<td>100</td>
<td>33.6</td>
</tr>
<tr>
<td>Briscoe et al., 2002</td>
<td>303 infants &gt;34 weeks gestation having blood drawn in first week of life</td>
<td>18 TcB value, mean 36 hours, forehead</td>
<td>&gt;14.6 mg/dL</td>
<td>100</td>
<td>45</td>
</tr>
<tr>
<td>Dai et al., 1996</td>
<td>45 healthy term infants</td>
<td>17 TcB value, &gt;24 hours, forehead</td>
<td>&gt;15.2 mg/dL</td>
<td>100</td>
<td>68</td>
</tr>
<tr>
<td>Sanpavat &amp; Nuchprayoon, 2007</td>
<td>196 premature infants &lt;38 weeks gestation with visually observed jaundice</td>
<td>TcB value 6, mean 4.5 days, forehead</td>
<td>≥6 mg/dL</td>
<td>97.8</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TcB value 12, mean 4.5 days, forehead</td>
<td>≥12 mg/dL</td>
<td>53.1</td>
<td>88.9</td>
</tr>
<tr>
<td>Schmidt et al., 2009</td>
<td>31 preterm neonates 32-34 weeks gestational age</td>
<td>&gt;4 mg/dL, mean 58.8 hours, sternum</td>
<td>&gt;6 mg/dL</td>
<td>98</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;8 mg/dL, mean 58.8 hours, sternum</td>
<td>&gt;10 mg/dL</td>
<td>93</td>
<td>74</td>
</tr>
</tbody>
</table>
## Screening - TcB

### TcB screening for subsequent significant hyperbilirubinemia

<table>
<thead>
<tr>
<th>Study</th>
<th>Pop.</th>
<th>Cutoff, Timing</th>
<th>Subsequent hyperbilirubinemia</th>
<th>Sens (%)</th>
<th>Spec (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bhat &amp; Rao, 2008</td>
<td>461 healthy term newborns born between 37 and 42 weeks gestation</td>
<td>&gt;5 TcBI, 24 hours</td>
<td>≥17mg/dl at &gt;72 hours of age</td>
<td>100</td>
<td>35.5</td>
<td>24.8</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;8 TcBI, 48 hours</td>
<td></td>
<td>100</td>
<td>52.6</td>
<td>31</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;7 TcBI, 24 hours</td>
<td></td>
<td>83.9</td>
<td>83.6</td>
<td>52.3</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;11 TcBI, 48 hours</td>
<td></td>
<td>44.4</td>
<td>95.5</td>
<td>67.9</td>
<td>88.9</td>
</tr>
<tr>
<td>Carbonell et al., 2001</td>
<td>2004 healthy term newborns of 37-42 weeks gestational age</td>
<td>&gt;13, 48 hours, sternum</td>
<td>≥17mg/dl at &gt;72 hours of age</td>
<td>98</td>
<td>32</td>
<td>8</td>
<td>99.6</td>
</tr>
</tbody>
</table>
Screening - Risk Nomogram

Predictive characteristics of TSB risk zones on Bhutani nomogram for subsequent hyperbilirubinemia

<table>
<thead>
<tr>
<th>Percentile</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Above 95th</td>
<td>54</td>
<td>96.2</td>
<td>39.5</td>
<td>97.8</td>
</tr>
<tr>
<td>Above 75th</td>
<td>90.5</td>
<td>84.7</td>
<td>21.6</td>
<td>99.5</td>
</tr>
<tr>
<td>Above 40th</td>
<td>100</td>
<td>64.7</td>
<td>11.6</td>
<td>100</td>
</tr>
</tbody>
</table>

*From Bhutani et al, 1999
## Screening - Risk Nomogram

Predictive characteristics of TcB values on Bhutani nomogram for subsequent hyperbilirubinemia

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Timing, Cutoff (%tile)</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bhutani et al., 2000</td>
<td>490 term and near-term newborns at discharge from well nursery</td>
<td>12-98 hours, &gt;75th</td>
<td>100</td>
<td>88.1</td>
<td>32.9</td>
<td>100</td>
</tr>
<tr>
<td>Dalal et al., 2009</td>
<td>358 neonates born at ≥35 weeks of gestation</td>
<td>30-48 hours, &gt;75th</td>
<td>82.6</td>
<td>79</td>
<td>41.2</td>
<td>95.1</td>
</tr>
</tbody>
</table>
Underestimation of TSB level was the most common diagnostic error using clinician’s visual assessment alone.

In infants with jaundice, the visual assessment grading system did not prove accurate in approximating bilirubin level or risk of developing subsequent hyperbilirubinemia.

TcB screening studies agreed on the utility of using such screening to rule out subsequent hyperbilirubinemia in infants with TSB values below a selected cutoff that provides a high NPV.
Screening Summary

- Interpretation of risk of subsequent hyperbilirubinemia is possible with an hour-specific bilirubin nomogram based on TSB or TcB values.

- Multi-hospital universal bilirubin screening (TSB or TcB) was associated with a significantly lower incidence of hyperbilirubinemia and lower rates of hospital readmissions due to bilirubin levels.
Screening - Remaining Questions

- What is the optimal approach for newborn screening for hyperbilirubinemia?
- Do risk factor assessments improve prediction of developing hyperbilirubinemia leading to kernicterus?
- What follow-up practices should be in place for newborns found to have an intermediate risk level by bilirubin screening?
- Do outpatient facilities have the capacity to handle follow-up visits for screen positive infants?
- What are the potential harms or risks associated with screening?
- Has there been population-based pilot screening?
- What would be the effect of taking bilirubin screening in its current form to state mandated newborn screening?
- What proportion of cases of kernicterus would be prevented by screening?
Key Questions - Treatment

- What methods exist to treat neonatal hyperbilirubinemia and what is their effectiveness? What is the relationship between outcomes and the timing of treatment intervention?

- What is the availability of treatment?

- What are the potential harms or risks associated with treatment?

- Does treating neonatal hyperbilirubinemia reduce the incidence of kernicterus?
Treatment - Methods

- Phototherapy
- Exchange transfusion
Treatment - Phototherapy

- Phototherapy effectively decreases levels of TSB in the neonatal period
- Effectiveness of phototherapy varies significantly depending on infant age, gender, and gestational age
- Indirect evidence of the wide availability of treatment
- Physical complications associated with phototherapy include fluid loss, temperature instability and corneal damage; two most common reported are skin rash and diarrhea
- No evidence of disruption in mother-child attachment after the first year of life
Treatment - Exchange Transfusion

- Adverse events common with EcT
- Mortality rate of EcT is approximately 0.53 per 100 patients and 0.3 per 100 procedures
- Morbidity rate 12-15.3%
- Bilirubin level to perform EcT remains controversial
Treatment - Outcomes

• Mixed results regarding the reversal of neurological and developmental symptoms after treatment
  – 3 studies suggest no or minimal resolution of neurological and developmental symptoms after treatment
  – 6 studies, including ones with longer follow up periods, show recovery from early acute clinical manifestations of hyperbilirubinemia after treatment

• Indirect evidence shows very early symptomatic and presymptomatic infants treated with phototherapy remain normal and prevents development of further clinical manifestations due to hyperbilirubinemia through all follow-up examinations
Treatment - Harms

Phototherapy
- Fluid loss
- Temperature instability
- Skin rash
- Diarrhea
- Corneal damage
- Bronze baby syndrome
- Behavioral changes (crying episodes, poorer scores in orientation items)

Exchange Transfusion
- Mortality rate has been calculated as 0.53/100 patients and 0.3/100 procedures
- Morbidity rate has been noted as 12-15.3%
- One study found 74% of EcTs were associated with an adverse event
- Summarized in Table 15 of evidence review
Treatment - Remaining Questions

- Does treating neonatal hyperbilirubinemia prevent kernicterus?
- What is the availability of treatment?
Key Questions - Economics

• What are the costs associated with the screening test?

• What are the costs associated with confirmatory testing, and the failure to find at risk newborns in the pre-symptomatic period?

• What are the costs associated with treatment?

• What is the cost-effectiveness of newborn screening for neonatal hyperbilirubinemia?
Five papers identified as including cost and/or economic outcomes related to screening for hyperbilirubinemia

- Four cost analyses only (no evaluation of outcomes)
  - Studies reported costs of jaundice readmission (1), test cost (1), cost of hyperbilirubinemia-related hospitalization (1) with varying levels of quality
  - One study reported data more than 20 years old
  - Other studies reported data from one institution
  - One study (jaundice admission) used statewide data (from CA)
  - One international study not applicable to US setting

Economics articles reported limited cost data but did not evaluate the cost-effectiveness or cost-benefit of newborn screening for hyperbilirubinemia
Cost-Effectiveness Analysis

• One identified paper was a cost-effectiveness analysis of strategies to prevent kernicterus in newborns
  – Main outcome: Cost per case of kernicterus prevented
  – Results of Base Case Analysis: $5,743,905 per case prevented using predischarge serum bilirubin testing
  – Sensitivity analysis: Screening strategies are unlikely to be cost-saving and will require an investment for health benefits associated with averted cases of kernicterus
  – Difficult to evaluate whether or not these screening strategies can be considered cost-effective without the use of QALYs as an outcome
Economics - Remaining Questions

• What are the costs associated with the screening test and follow-up for newborns found to have an intermediate risk level by bilirubin screening?
• What are the costs associated with confirmatory testing, and the failure to find at risk newborns in the pre-symptomatic period?
• What are the costs associated with treatment?
• What is the cost-effectiveness of newborn screening for neonatal hyperbilirubinemia?
### Key Findings

<table>
<thead>
<tr>
<th>Number of studies; subjects</th>
<th>Design</th>
<th>Risk of bias/study quality</th>
<th>Consistency</th>
<th>Directness</th>
<th>Precision</th>
<th>Strength of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>High total serum bilirubin concentration leads to acute clinical manifestations</td>
<td>Case series</td>
<td>Good</td>
<td>Inconsistent</td>
<td>Direct</td>
<td>Imprecise</td>
<td>Fair</td>
</tr>
<tr>
<td>22; 48,569</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Summary: Direct evidence that, when compared to controls, newborns with increased total serum bilirubin levels experienced an increase in acute clinical manifestations.

### Additional sensitivity of TcB over visual assessment for hyperbilirubinemia

<table>
<thead>
<tr>
<th>Number of studies; subjects</th>
<th>Design</th>
<th>Risk of bias/study quality</th>
<th>Consistency</th>
<th>Directness</th>
<th>Precision</th>
<th>Strength of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>2; 863</td>
<td>Prospective Cohort</td>
<td>Good</td>
<td>Inconsistent</td>
<td>Direct</td>
<td>Imprecise</td>
<td>Fair</td>
</tr>
</tbody>
</table>

Summary: TcB detects most cases of neonatal hyperbilirubinemia that may necessitate further assessment. Adding TcB to visual assessment increased the sensitivity of predicting TSB levels of 12.1-15 mg/dL from 5.7% to 30.8%. Evidence suggests that TcB leads to less subsequent TSB blood draws and a greater number of newborns identified at and above the higher risk 75th percentile.
# Key Findings

## Specificity and sensitivity of risk assessment/ predischarge screening prediction

<table>
<thead>
<tr>
<th>Number of studies; subjects</th>
<th>Design</th>
<th>Risk of bias/study quality</th>
<th>Consistency</th>
<th>Directness</th>
<th>Precision</th>
<th>Evidence strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>7; 20,713</td>
<td>Prospective Cohort</td>
<td>Good</td>
<td>Inconsistent</td>
<td>Direct</td>
<td>Imprecise</td>
<td>-</td>
</tr>
</tbody>
</table>

Summary: The specificity of the predischarge screening and risk assessment nomogram for at and above the 75th risk percentile is high (84.7% for TSB, ≥79% for TcB). The sensitivity at and above the 75th risk percentile is also high (90.5% for TSB, >82% for TcB). At and above the 40th percentile, the specificity is 64.7% (TSB) or 38.4% (TcB) and the sensitivity is 100% (TSB) or 94.1% (TcB). The evidence does not address whether this prediction assessment decreased the incidence of kernicterus.

## Screening for hyperbilirubinemia prevents kernicterus

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0;0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>Poor</td>
</tr>
</tbody>
</table>

Summary: No data identified regarding whether screening for neonatal hyperbilirubinemia prevents kernicterus.
### Effectiveness of early intervention for hyperbilirubinemia

<table>
<thead>
<tr>
<th>Number of studies; subjects</th>
<th>Design</th>
<th>Risk of bias/study quality</th>
<th>Consistency</th>
<th>Directness</th>
<th>Precision</th>
<th>Strength of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>11; 18,329</td>
<td>Prospective Cohort</td>
<td>Good</td>
<td>Inconsistent</td>
<td>Indirect</td>
<td>Imprecise</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

Evidence Summary: Indirect evidence that early intervention is associated with improved outcomes for those with neonatal hyperbilirubinemia. Evidence indicates treatment lowers elevated bilirubin concentration levels, and lower bilirubin level is associated with less acute clinical manifestations. No evidence that treatment prevents kernicterus.
## Next Steps

### Experts and Advocates to Consult

<table>
<thead>
<tr>
<th>Experts and Advocates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vinod Bhutani, MD, PhD</td>
</tr>
<tr>
<td>Coleen Boyle, PhD, MSH</td>
</tr>
<tr>
<td>Karen Dixon, PhD</td>
</tr>
<tr>
<td>Gabriel Escobar, MD</td>
</tr>
<tr>
<td>Thomas Hegyi, MD</td>
</tr>
<tr>
<td>Lois Johnson-Hamerman, MD</td>
</tr>
<tr>
<td>Michael Kaplan, MB, ChBM</td>
</tr>
<tr>
<td>Jeffrey Maisels, MD</td>
</tr>
<tr>
<td>Marie Mann, MD, MPH</td>
</tr>
<tr>
<td>Thomas B. Newman, MD, MPH</td>
</tr>
<tr>
<td>Lu-Ann Papile, MD</td>
</tr>
<tr>
<td>Sue Sheridan, MIM, MBA</td>
</tr>
<tr>
<td>Steven M. Shapiro MD, MSHA</td>
</tr>
<tr>
<td>Ann Stark, MD</td>
</tr>
<tr>
<td>David Stevenson, MD</td>
</tr>
<tr>
<td>Marshalyn Yeargin-Allsopp, MD</td>
</tr>
</tbody>
</table>

Recommendations of additional experts to contact are welcome.
Questions for Experts

• How are infants at risk of subsequent hyperbilirubinemia, who do not require treatment, managed?
• What would be the effect of taking bilirubin screening in its current form to state mandated newborn screening?
Thank you
2004 AAP Phototherapy Guidelines

*Reproduced with permission from Pediatrics, Vol. 114, Page 304, Copyright © 2004 by the AAP*
2004 AAP Exchange Transfusion Guidelines

*Reproduced with permission from *Pediatrics*, Vol. 114, Page 305, Copyright © 2004 by the AAP